GL1X · GenesisL1 explorer

Research workbench

N288Q-N321Q mutant BETA-LACTAMASE DERIVED FROM CHROMOHALOBACTER SP.560 (Condition-2B)

Analyse N288Q-N321Q mutant BETA-LACTAMASE DERIVED FROM CHROMOHALOBACTER SP.560… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3WS5
Type
protein
Length
1,073 residues
Chains
3
Method
x-ray diffraction
Collection
MolNFT v2 / PDB Bank
Contract
0xd58B01f6C18086e5202cdC5D7Ad3E41790360102
Owner
0xF4e1AA6f26B7DA48EeAD9B24a97927303eeA07b8
Resolution
2.8
Source
Chromohalobacter sp. 560
Molecule
Beta-lactamase
EC
3.5.2.6
UniProt
Q76LX5
Ligands
SR, CA, CL
Pockets
6 · best druggability 0.74

Structure

x-ray diffraction · resolution 2.8 · 3 distinct chains · 40% helix, 20% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ABeta-lactamase (EC 3.5.2.6)protein35740% helix, 21% strandQ76LX5
BBeta-lactamase (EC 3.5.2.6)protein35940% helix, 19% strandQ76LX5
CBeta-lactamase (EC 3.5.2.6)protein35740% helix, 19% strandQ76LX5

Ligands and binding sites

  • SR · Strontium ion · metal · chains A
  • CA · Calcium ion · metal · chains B
  • CL · Chloride ion · ion · 3 copies · chains A, B, C

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

6 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110170.740.7797CL
27540.690.7672empty
32930.560.7643CL
42900.560.7640CL
5510.270.7418empty

Interfaces

2 interfaces between chains.

  • A–C · 388 Ų buried · 1 hydrogen bond · protein-protein
  • A–B · 326 Ų buried · 5 hydrogen bonds · protein-protein

Compared structures

  • 3WS5 · N288Q-N321Q mutant beta-lactamase derived from chromohalobacter SP.560 (condition-2B) · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.